Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts

Arthritis Research and Therapy

Volumn 8, Issue 1, 2005, Pages

  Chizzolini, Carlo ^a   Parel, Yann ^a   Scheja, Agneta ^b   Dayer, Jean Michel ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350523842     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1860     Document Type: Article

References (67)

1. Jelaska A, Strehlow D, Korn JH: Fibroblast heterogeneity in physiological conditions and fibrotic disease. Springer Semin Immunopathol 1999, 21:385-395.
2. Brouty-Boye D, Doucet C, Clay D, Le Bousse-Kerdiles MC, Lampidis TJ, Azzarone B: Phenotypic diversity in human fibroblasts from myelometaplasic and non-myelometaplasic hematopoietic tissues. Int J Cancer 1998, 76:767-773.
3. Brouty-Boye D, Pottin-Clemenceau C, Doucet C, Jasmin C, Azzarone B: Chemokines and CD40 expression in human fibroblasts. Eur J Immunol 2000, 30:914-919.
4. Fukuda K, Yamada N, Fujitsu Y, Kumagai N, Nishida T: Inhibition of eotaxin expression in human corneal fibroblasts by interferon-gamma. Int Arch Allergy Immunol 2002, 129:138-144.
5. Yu B, Koga T, Urabe K, Moroi Y, Maeda S, Yanagihara Y, Furue M: Differential regulation of thymus- and activation-regulated chemokine induced by IL-4, IL-13, TNF-alpha and IFN-gamma in human keratinocyte and fibroblast. J Dermatol Sci 2002, 30:29-36.
6. Teran LM, Mochizuki M, Bartels J, Valencia EL, Nakajima T, Hirai K, Schroder JM: Th1- and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts. Am J Respir Cell Mol Biol 1999, 20:777-786.
7. Struyf S, Van Collie E, Paemen L, Put W, Lenaerts JP, Proost P, Opdenakker G, Van Damme J: Synergistic induction of MCP-1 and -2 by IL-1beta and interferons in fibroblasts and epithelial cells. J Leukoc Biol 1998, 63:364-372.
8. Fukuda K, Fujitsu Y, Seki K, Kumagai N, Nishida T: Differential expression of thymus- and activation-regulated chemokine (CCL17) and macrophage-derived chemokine (CCL22) by human fibroblasts from cornea, skin, and lung. J Allergy Clin Immunol 2003, 111:520-526.
9. Baggiolini M: Chemokines and leukocyte traffic. Nature 1998, 392:565-568.
10. Gerard C, Rollins BJ: Chemokines and disease. Nat Immunol 2001, 2:108-115.
11. Gharaee-Kermani M, Denholm EM, Phan SH: Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996, 271:17779-17784.
12. Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T: Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. J Immunol 2000, 164:6174-6179.
13. Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, Scholmerich J, Michel BA, Gay RE, Matucci-Cerinic M, et al.: Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: Role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001, 44:2665-2678.
14. Luzina IG, Atamas SP, Wise R, Wigley FM, Xiao HQ, White B: Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol 2002, 26:549-557.
15. Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos JL: Chemokine expression by systemic sclerosis fibroblasts: Abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 2001, 44:1382-1386.
16. Yamamoto T, Eckes B, Krieg T: High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 2001, 31:2936-2941.
17. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C, Azzarone B: Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest 1998, 101 2129-2139.
18. Karpus WJ, Lukacs NW, Kennedy KJ, Smith WS, Hurst SD, Barrett TA: Differential CC chemokine-induced enhancement of T helper cell cytokine production. J Immunol 1997, 158:4129-4136.
19. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ: Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000, 404:407-411.
20. Hogaboam CM, Bone-Larson CL, Lipinski S, Lukacs NW, Chensue SW, Strieter RM, Kunkel SL: Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models. J Immunol 1999, 163:2193-2201.
21. Zhu Z, Ma B, Zheng T, Homer RJ, Lee CG, Charo IF, Noble P, Elias JA: IL-13-induced chemokine responses in the lung: Role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 2002, 168:2953-2962.
22. Gharaee-Kermani M, McCullumsmith RE, Charo IF, Kunkel SL, Phan SH: CC-chemokine receptor 2 required for bleomycininduced pulmonary fibrosis Cytokine 2003, 24:266-276.
23. Distler O, Rinkes B, Hohenleutner U, Scholmerich J, Landthaler M, Lang B, Gay S, Muller-Ladner U: Expression of RANTES in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis Rheumatol Int 1999, 19:39-46.
24. Hasegawa M, Sato S, Takehara K: Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP- 1beta) in patients with systemic sclerosis: MCP-1 and MIP- 1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999, 117:159-165.
25. Atamas SP, Luzina IG, Choi J, Tsymbalyuk N, Carbonetti NH, Singh IS, Trojanowska M, Jimenez SA, White B: Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am J Respir Cell Mol Biol 2003, 29:743-749.
26. Ong VH, Evans LA, Shiwen X, Fisher IB, Rajkumar V, Abraham DJ, Black CM, Denton CP: Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum 2003, 48:1979-1991.
27. Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Takehara K, Sato S: Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol 2003, 30:1524-1528.
28. Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, Strieter RM: Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol 1999, 162 5511-5518.
29. Keane MP, Arenberg DA, Lynch JP, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, et al.: The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997, 159:1437-1443.
30. Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM: IFN-gamma-inducible protein-10 attenuates bleomycin- induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 1999, 163:5686-5692.
31. Tager AM, Kradin RL, LaCamera P, Bercury SD, Campanella GS, Leary CP, Polosukhin V, Zhao LH, Sakamoto H, Blackwell TS, Luster AD: Inhibition of pulmonary fibrosis by the chemokine IP- 10/CXCL10. Am J Respir Cell Mol Biol 2004, 31:395-404.
32. Chizzolini C: T lymphocyte and fibroTlast interactions: the case of skin involvement in systemic sclerosis and other examples. Springer Semin Immunopathol 1999, 21:431-450.
33. Atamas SP, Yurovsky VV, Wise R, Wigley FM, Goter Robinson CJ, Henry P, Alms WJ, White B: Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999, 42 1168-1178.
34. Mavilia C, Scaletti C, Romagnani P, Carossino AM, Pignone A, Emmi L, Pupilli C, Pizzolo G, Maggi E, Romagnani S: Type 2 helper T cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997, 151:1751-1758.
35. Scaletti C, Vultaggio A, Bonifacio S, Emmi L, Torricelli F, Maggi E, Romagnani S, Piccinni MP: Th2-oriented profile of male offspring T cells present in women with systemic sclerosis and reactive with maternal major histocompatibility complex antigens. Arthritis Rheum 2002, 46:445-450.
36. Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A, Dayer JM: Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor α. Arthritis Rheum 2003, 48:2593-2604.
37. Postlethwaite AE, Holness MA, Katai H, Raghow R: Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992, 90:1479-1485.
38. Serpier H, Gillery P, Salmon-Ehr V, Garnotel R, Georges N, Kalis B, Maquart FX: Antagonistic effects of interferon-gamma and interleukin-4 on fibroblast cultures. J Invest Dermatol 1997, 109:158-162.
39. +T cells from scleroderma patients. Arthritis Rheum 2003, 48:2262-2274.
40. Chizzolini C, Rezzonico R, Ribbens C, Burger D, Wollheim FA, Dayer JM: Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells. Different sensitivity to inhibition of systemic sclerosis and control fibroblasts. Arthritis Rheum 1998, 41:2039-2047.
41. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590.
42. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
43. Edwards CK, Martin SW, Seely J, Kinstler O, Buckel S, Bendele AM, Ellen Cosenza M, Feige U, Kohno T: Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv Drug Deliv Rev 2003, 55:1315-1336.
44. Burger D, Chicheportiche R, Giri JG, Dayer JM: The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 1995, 96:38-41.
45. Molnarfi N, Hyka-Nouspikel N, Gruaz L, Dayer JM, Burger D: The production of IL-1 receptor antagonist in IFN-beta-stimulated human monocytes depends on the activation of phosphatidylinositol 3-kinase but not of STAT1. J Immunol 2005, 174:2974-2980.
46. Chizzolini C, Chicheportiche R, Burger D, Dayer JM: Human Th1 cells preferentially induce interleukin (IL)-1beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes. Eur J Immunol 1997, 27:171-177.
47. Ferrari-Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM: Human lung tissue macrophages, but not alveolar macrophages, express matrix metalloproteinases after direct contact with activated T lymphocytes. Am J Respir Cell Mol Biol 2001, 24:442-451.
48. Chizzolini C, Rezzonico R, De Luca C, Burger D, Dayer JM: Th2 cells membrane factors in association with IL-4 enhance matrix metalloproteinase-1 (MMP-1) while decreasing MMP-9 production by granulocyte-macrophage colony-stimulating factor-differentiated on human monocytes. J Immunol 2000, 164:5952-5960.
49. Atamas SP, White B: The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 2003, 15:772-777.
50. Gruschwitz MS, Vieth G: Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by intreferon-gamma and tumor necrosis factor-alpha in the early disease stage. Arthritis Rheum 1997, 40:540-550.
51. Rollins BJ: MCP-1, MCP-2, MCP-3, MCP-4, and MCP-5. In Cytokine Reference Edited by: Oppenheim JJ, Feldman M. London: Academic Press; 2001:1145-1160.
52. Rollins BJ, Pober JS: Interleukin-4 induces the synthesis and secretion of MCP-1/JE by human endothelial cells. Am J Pathol 1991, 138:1315-1319.
53. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, Strieter RM, Kunkel SL, Massa MC, Barr WG, et al.: In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease Pathobiology 1993, 61:239-246.
54. Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K: Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts J Rheumatol 1998, 25:296-301.
55. Seitz M, Loetscher P, Dewald B, Towbin H, Ceska M, Baggiolini M: Production of interleukin-1 receptor antagonist, inflammatory chemotactic proteins, and prostaglandin E by rheumatoid and osteoarthritic synoviocytes: Regulation by IFN-gamma and IL- 4. J Immunol 1994, 152:2060-2065.
56. Oliveira IC, Mukaida N, Matsushima K, Vilcek J: Transcriptional inhibition of the interleukin-8 gene by interferon is mediated by the NF-kappa B site. Mol Cell Biol 1994, 14:5300-5308.
57. Cassatella MA, Gasperini S, Calzetti F, McDonald PP, Trinchieri G: Lipopolysaccharide-induced interleukin-8 gene expression in human granulocytes: Transcriptional inhibition by interferongamma. Biochem J 1995, 310:751-755.
58. Bosco MC, Gusella GL, Espinoza-Delgado I, Longo DL, Varesio L: Interferon-gamma upregulates interleukin-8 gene expression in human monocytic cells by a posttranscriptional mechanism. Blood 1994, 83:537-542.
59. Sakuta T, Tokuda M, Tamura M, Jimi E, Ikebe T, Koba T, Nagaoka S, Takada H: Dual regulatory effects of interferon-alpha, -beta, and -gamma on interleukin-8 gene expression by human gingival fibroblasts in culture upon stimulation with lipopolysaccharide from Prevotella intermedia, interleukin-1alpha, or tumor necrosis factor-alpha. J Dent Res 1998, 77:1597-1605.
60. Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, Hamid Q, Luster AD: The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells J Immunol 1999, 162:3549-3558.
61. Fujii H, Shimada Y, Hasegawa M, Takehara K, Sato S: Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci 2004, 35:43-51.
62. Yamamoto T, Eckes B, Krieg T: High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 2001, 31:2936-2941.
63. Natarajan R, Gupta S, Fisher BJ, Ghosh S, Fowler AA: Nitric oxide suppresses IL-8 transcription by inhibiting c-Jun N-terminal kinase-induced AP-1 activation. Exp Cell Res 2001, 266 203-212.
64. Neff L, Zeisel M, Druet V, Takeda K, Klein JP, Sibilia J, Wachsmann D: ERK 1/2- and JNKs-dependent synthesis of interleukins 6 and 8 by fibroblast-like synoviocytes stimulated with protein I/II, a modulin from oral streptococci, requires focal adhesion kinase. J Biol Chem 2003, 278:27721-27728.
65. Ping D, Boekhoudt G, Zhang F, Morris A, Philipsen S, Warren ST, Boss JM: Sp1 binding is critical for promoter assembly and activation of the MCP-1 gene by tumor necrosis factor. J Biol Chem 2000, 275 1708-1714.
66. Parry GC, Martin T, Felts KA, Cobb RR: IL-1beta-induced monocyte chemoattractant protein-1 gene expression in endothelial cells is blocked by proteasome inhibitors. Arterioscler Thromb Vasc Biol 1998, 18:934-940.
67. Ohmori Y, Schreiber RD, Hamilton TA: Synergy between interferon- gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. J Biol Chem 1997, 272:14899-14907.